These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 35208221)

  • 1. Glucagon-Like Peptide-1 Receptor Agonist Semaglutide Improves Eating Behavior and Glycemic Control in Japanese Obese Type 2 Diabetic Patients.
    Masaki T; Ozeki Y; Yoshida Y; Okamoto M; Miyamoto S; Gotoh K; Shibata H
    Metabolites; 2022 Feb; 12(2):. PubMed ID: 35208221
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight, eating behavior, and glycemic control, in Japanese obese type 2 diabetes.
    Fujishima Y; Maeda N; Inoue K; Kashine S; Nishizawa H; Hirata A; Kozawa J; Yasuda T; Okita K; Imagawa A; Funahashi T; Shimomura I
    Cardiovasc Diabetol; 2012 Sep; 11():107. PubMed ID: 22973968
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity.
    Blundell J; Finlayson G; Axelsen M; Flint A; Gibbons C; Kvist T; Hjerpsted JB
    Diabetes Obes Metab; 2017 Sep; 19(9):1242-1251. PubMed ID: 28266779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Effectiveness of GLP-1 Receptor Agonist Semaglutide on Body Composition in Elderly Obese Diabetic Patients: A Pilot Study.
    Ozeki Y; Masaki T; Kamata A; Miyamoto S; Yoshida Y; Okamoto M; Gotoh K; Shibata H
    Medicines (Basel); 2022 Sep; 9(9):. PubMed ID: 36135828
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differences in weight loss and safety between the glucagon-like peptide-1 receptor agonists: A non-randomized multicenter study from the titration phase.
    Seijas-Amigo J; Salgado-Barreira Á; Castelo-Dominguez R; Pérez-Álvarez MT; Ponce-Piñón B; Fernández-Silva M; Rodríguez-Barreiro M; Pereira-Pía M; Iglesias-Moreno JM; Gago-García M; Montáns-García R; Fernandez-Perez A; FragaGayoso D; Fernandez-Montenegro M; Riveiro-Barciela B; Rilla-Villar N; Cordero A; RodríguezMañero M; González-Juanatey JR
    Prim Care Diabetes; 2023 Aug; 17(4):366-372. PubMed ID: 37230813
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Impact of Semaglutide, a Glucagon-Like Peptide-1 Receptor Agonist, on Obesity Management: A Review.
    Alorfi NM; Algarni AS
    Clin Pharmacol; 2022; 14():61-67. PubMed ID: 35958046
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness and Tolerability of Once-Weekly GLP-1 Receptor Agonists in Clinical Practice: A Focus on Switching Between Once-Weekly Molecules in Type 2 Diabetes.
    Di Dalmazi G; Coluzzi S; Baldassarre MPA; Ghit A; Graziano G; Rossi MC; Ciappini B; Milo M; Carrieri F; Nicolucci A; Consoli A; Formoso G
    Front Endocrinol (Lausanne); 2022; 13():892702. PubMed ID: 35909534
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of semaglutide on cardiovascular risk factors and eating behaviors in type 2 diabetes.
    Di Folco U; Vallecorsa N; Nardone MR; Pantano AL; Tubili C
    Acta Diabetol; 2022 Oct; 59(10):1287-1294. PubMed ID: 35842847
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness in Real World of Once Weekly Semaglutide in People with Type 2 Diabetes: Glucagon-Like Peptide Receptor Agonist Naïve or Switchers from Other Glucagon-Like Peptide Receptor Agonists: Results from a Retrospective Observational Study in Umbria.
    Di Loreto C; Minarelli V; Nasini G; Norgiolini R; Del Sindaco P
    Diabetes Ther; 2022 Mar; 13(3):551-567. PubMed ID: 35230650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rapid Improvement in Weight, Body Composition, and Glucose Variability With Semaglutide in Type 1 Diabetes.
    Gad H; Malik RA
    Cureus; 2024 Jun; 16(6):e61577. PubMed ID: 38962634
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exploring the wider benefits of semaglutide treatment in obesity: insight from the STEP program.
    O'Neil PM; Rubino DM
    Postgrad Med; 2022 Jan; 134(sup1):28-36. PubMed ID: 36691307
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and tolerability of oral semaglutide in Japanese patients with type 2 diabetes mellitus: Analysis report from diabetes specialist clinics.
    Inokuchi T; Fukumoto Y; Lee G; Yokomizo Y; Tanaka K; Chosa M; Doi M; Tamaki N; Goto S; Ichikawa K; Kobayashi K
    J Diabetes Investig; 2024 May; ():. PubMed ID: 38700282
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of oral semaglutide on energy intake, food preference, appetite, control of eating and body weight in subjects with type 2 diabetes.
    Gibbons C; Blundell J; Tetens Hoff S; Dahl K; Bauer R; Baekdal T
    Diabetes Obes Metab; 2021 Feb; 23(2):581-588. PubMed ID: 33184979
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glucagon-like Peptide-1 Receptor Agonist Treatment With Semaglutide in Type 1 Diabetes.
    Raven LM; Greenfield JR; Muir CA
    JCEM Case Rep; 2023 Jan; 1(1):luac017. PubMed ID: 37908242
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of Switching from Liraglutide or Dulaglutide to Subcutaneous Semaglutide on Glucose Metabolism and Treatment Satisfaction in Patients with Type 2 Diabetes: Protocol for a Multicenter, Prospective, Randomized, Open-Label, Blinded-Endpoint, Parallel-Group Comparison Study (The SWITCH-SEMA 1 Study).
    Nomoto H; Oba-Yamamoto C; Takahashi Y; Takeuchi J; Nagai S; Yokoyama H; Taneda S; Kurihara Y; Aoki S; Kameda H; Cho KY; Nakamura A; Atsumi T; Miyoshi H
    Diabetes Ther; 2021 Mar; 12(3):955-964. PubMed ID: 33491111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of Patient-Reported Satisfaction and Clinical Efficacy of Once-Weekly Semaglutide in Patients with Type 2 Diabetes: An Ambispective Study.
    Al Hayek AA; Al Dawish MA
    Adv Ther; 2022 Apr; 39(4):1582-1595. PubMed ID: 35119622
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preference for Oral and Injectable GLP-1 RA Therapy Profiles in Japanese Patients with Type 2 Diabetes: A Discrete Choice Experiment.
    Igarashi A; Bekker Hansen B; Langer J; Tavella F; Collings H; Davies N; Wyn R
    Adv Ther; 2021 Jan; 38(1):721-738. PubMed ID: 33245530
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1-7 trials.
    Aroda VR; Ahmann A; Cariou B; Chow F; Davies MJ; Jódar E; Mehta R; Woo V; Lingvay I
    Diabetes Metab; 2019 Oct; 45(5):409-418. PubMed ID: 30615985
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful treatment of binge eating disorder with the GLP-1 agonist semaglutide: A retrospective cohort study.
    Richards J; Bang N; Ratliff EL; Paszkowiak MA; Khorgami Z; Khalsa SS; Simmons WK
    Obes Pillars; 2023 Sep; 7():100080. PubMed ID: 37990682
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral semaglutide versus injectable glucagon-like peptide-1 receptor agonists: a cost of control analysis.
    Hansen BB; Nuhoho S; Ali SN; Dang-Tan T; Valentine WJ; Malkin SJP; Hunt B
    J Med Econ; 2020 Jun; 23(6):650-658. PubMed ID: 31990244
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.